Alemtuzumab, a Monoclonal Antibody against CD52: Hopes and Fears

DOI Web Site PubMed
  • 森 雅裕
    千葉大学大学院医学研究院神経内科学

Bibliographic Information

Other Title
  • 特集 分子を撃つ　神経疾患治療の新しい水平線 CD52:アレムツズマブ
  • CD52 : アレムツズマブ

Search this article

Description

CD52, an antigen expressed on immune cells including mature T lymphocytes, is thought to be involved in immunomodulatory mechanisms. Alemtuzumab is a humanized monoclonal antibody against CD52, which causes a marked and long-term decrease in immune cells, especially CD4-positive T lymphocytes. A few randomized clinical trials have revealed the efficacy of alemtuzumab to be much greater than that of interferon-β in patients with relapsing-remitting multiple sclerosis. However, the development of other autoimmune disorders, including autoimmune thyroid disorders and thrombocytic purpura, because of alemtuzumab application has been considered an obstacle in its widespread use.

Journal

  • BRAIN and NERVE

    BRAIN and NERVE 66 (10), 1179-1189, 2014-10-01

    株式会社医学書院

Keywords

Details 詳細情報について

Report a problem

Back to top